Evidence map›Paper›PMID 35624141›Full record

ReviewNature reviews. Endocrinology2022

Treating menopause - MHT and beyond.

Susan R Davis, Rodney J Baber

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07302750 (The Effectiveness of Artificial Intelligence-Assisted Relaxation and Breathing Training on Pain Intensity and Quality of Life in Postmenopausal Women), which is not on this map. Cited by 79 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 4 pooled it
19.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07302750 narecruitingnot on this mapstarted 2026, after this paper: background citation

The Effectiveness of Artificial Intelligence-Assisted Relaxation and Breathing Training on Pain Intensity and Quality of Life in Postmenopausal Women

TypeinterventionalSponsorBaskent UniversityRan2026 to 2027Enrolled48ConditionsPostmenopausal Period, Postmenopausal WomenArmsPhysiotherapist-Guided Relaxation and Breathing Training, Artificial Intelligence-Assisted Relaxation and Breathing Training, Control Group - No Structured Training Program
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 4 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Arquivos brasileiros de cardiologia · 2024
    Guideline
  4. Guideline
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Susan R DavisWomen's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. susan.davis@monash.edu.ORCID http://orcid.org/0000-0002-2955-0415
Rodney J BaberDepartment of Obstetrics and Gynaecology, University of Sydney, Sydney, NSW, Australia.
The Alfred Hospital · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Every woman who lives past midlife will experience menopause, which, by definition, is complete cessation of ovarian function. This process might occur spontaneously (natural menopause) or be iatrogenic (secondary menopause), and can be further classified as 'early' if it occurs before the age of 45 years and 'premature' if it occurs before the age of 40 years. Globally, the mean age of natural menopause is 48.8 years, with remarkably little geographic variation. A woman's age at menopause influences health outcomes in later life. Early menopause is associated with a reduced risk of breast cancer, but increased risks of premature osteoporosis, cardiovascular disease and premature death. The cardinal symptoms of menopause, and adverse health sequelae, are due to loss of ovarian oestrogen production. Consequently, menopausal hormone therapy (MHT) that includes oestrogen or an oestrogenic compound ameliorates menopausal symptoms, while preventing menopause-associated bone loss and cardiometabolic changes. Importantly, comprehensive care of postmenopausal women involves lifestyle optimization (attention to nutrition and physical activity, reducing alcohol consumption and not smoking) and treating other established chronic disease risk factors. This Review offers a commentary specifically on the contemporary use of MHT and novel pharmaceutical alternatives to manage menopausal symptoms.

Indexed as

Estrogen Replacement TherapyHormone Replacement TherapyAdultEstrogensFemaleHumansMenopauseMiddle AgedEstrogens

Identifiers

PMID35624141
OpenAlexW4281694941

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.